APA (7th ed.) Citation

Won, C. H., Park, C. W., Ahn, J., Ko, J. Y., Cho, S. H., Lee, Y. W., . . . Son, S. W. (2026). Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria. JEADV Clinical Practice, 5(2), 529. https://doi.org/10.1002/jvc2.70271

Chicago Style (17th ed.) Citation

Won, Chong Hyun, et al. "Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would Be Eligible for Treatment Based on the South Korean Reimbursement Criteria." JEADV Clinical Practice 5, no. 2 (2026): 529. https://doi.org/10.1002/jvc2.70271.

MLA (9th ed.) Citation

Won, Chong Hyun, et al. "Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would Be Eligible for Treatment Based on the South Korean Reimbursement Criteria." JEADV Clinical Practice, vol. 5, no. 2, 2026, p. 529, https://doi.org/10.1002/jvc2.70271.